ORIGINAL INVESTIGATION. Delay From Symptom Onset to Hospital Presentation for Patients With Non ST-Segment Elevation Myocardial Infarction

Size: px
Start display at page:

Download "ORIGINAL INVESTIGATION. Delay From Symptom Onset to Hospital Presentation for Patients With Non ST-Segment Elevation Myocardial Infarction"

Transcription

1 ORIGINAL INVESTIGATION Delay From Symptom Onset to Hospital Presentation for Patients With Non ST-Segment Elevation Myocardial Infarction Henry H. Ting, MD, MBA; Anita Y. Chen, MS; Matthew T. Roe, MD, MHS; Paul S. Chan, MD, MSc; John A. Spertus, MD, MPH; Brahmajee K. Nallamothu, MD, MPH; Mark D. Sullivan, MD, PhD; Elizabeth R. DeLong, PhD; Elizabeth H. Bradley, PhD; Harlan M. Krumholz, MD, SM; Eric D. Peterson, MD, MPH Background: Secular trends and factors associated with delay time from symptom onset to hospital presentation are known for patients with ST-segment elevation myocardial infarction (STEMI) but are less well-described for non-stemi. Methods: We studied patients with non- STEMI enrolled at 568 hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) National Quality Improvement Initiative from January 1, 2001, to December 31, We examined secular trends and factors associated with delay time and the association of delay time with in-hospital mortality. Results: Median delay time from symptom onset to hospital presentation was 2.6 hours (interquartile range, ) and has been stable from 2001 to 2006 (P value for trend,.16). After multivariable adjustment, factors associated with longer delay time included older age, female sex, nonwhite race, diabetes, and current smoking. In addition, compared with those who presented during weekday daytime ( 8 AM to 4 PM), patients who presented during weekday and weekend nights ( 12 AM to 8 AM) had a 24.7% and 24.3% shorter delay time, respectively (P). After multivariable adjustment, the odds ratio of in-hospital mortality for patients with delay times of 0 to 1 hour or less, more than 1 to 2 hours, more than 2 to 3 hours, and more than 3 to 6 hours compared with the reference group (delay time 6 hours) were 1.19 (95% confidence interval [CI], ), 0.91 (95% CI, ), 0.77 (95% CI, ), and 0.90 (95% CI, ), respectively. Conclusions: Long delay times are common and have not changed over time for patients with non-stemi. Because patients cannot differentiate whether symptoms are due to STEMI or non-stemi, early presentation is desirable in both instances. Arch Intern Med. 2010;170(20): Author Affiliations are listed at the end of this article. AMERICAN COLLEGE OF CARdiology/American Heart Association (ACC/AHA) guidelines recommend that patients who experience symptoms suggestive of acute coronary syndrome should call if those symptoms are unimproved or worsening after 5 CME available online at and questions on page 1788 minutes (class I). 1 Since patients typically cannot differentiate if their symptoms represent ST-segment elevation myocardial infarction (STEMI) or non-stemi, immediate presentation to the hospital after symptom onset is critical in both instances. For patients with STEMI, studies have documented that the average delay time from symptom onset to hospital presentation is 2 hours and has not decreased substantially despite multiple public education campaigns. 2-9 Furthermore, longer delays are associated with higher inhospital mortality in patients with STEMI. 3 See also page 1842 While delays from symptom onset to hospital presentation have been linked to worse outcomes in patients with STEMI, the impact of such delays in patients with non-stemi is unknown. Secular trends and factors associated with delay time have also not been evaluated for a contemporary, nationally representative cohort of patients with non-stemi. To address this, we undertook a study to evaluate delay time from the contemporary, communitybased, national registry Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA 1834

2 Guidelines (CRUSADE) National Quality Improvement Initiative. We specifically examined (1) the overall distribution of delay time, (2) secular trends in delay time, (3) factors associated with longer delays time, and (4) the association of delay time with in-hospital mortality. METHODS STUDY DESIGN AND POPULATION The details of the CRUSADE National Quality Improvement Initiative have been previously published Patients are eligible for the CRUSADE registry if they have ischemic symptoms lasting 10 or more minutes within 24 hours of hospital presentation in combination with high-risk features including STsegment depression, transient ST-segment elevation, and/or elevated cardiac biomarkers (creatine kinase MB or troponin I or T). Between January 1, 2001, and December 31, 2006, there were patients enrolled in CRUSADE at 568 hospitals. The following patients were excluded sequentially: those who had received a diagnosis of unstable angina (n=13 177), those who had an unknown date or time of symptom onset (n=26 604), and those who were transferred in from another hospital (n=23 788). Patients who were transferred out to another hospital were included in this analysis since the delay time from symptom onset to hospital presentation was available. The remaining patients with non-stemi comprised the study population for this analysis. DATA COLLECTION AND MEASURES Hospitals participating in CRUSADE collected data on patient demographic and clinical information, physician and hospital characteristics, medical histories, immediate use of medications within 24 hours of presentation, use and timing of invasive cardiac procedures, in-hospital outcomes, and discharge medications. Each hospital s institutional review board reviews and approves participation in CRUSADE, and because data are collected anonymously and without unique patient identifiers, informed consent is not required. Delay from symptom onset to hospital presentation was calculated from the documented date and time of symptom onset to the documented date and time of hospital arrival and was expressed as median and interquartile range (hours). Candidate factors evaluated for association with longer delay times included age; sex; race/ethnicity (categorized as white, black, Hispanic, Asian, or other/unknown); payer type (categorized as private/health maintenance organization, Medicare, Medicaid, or self-pay/none); medical history (family history of coronary artery disease, hypertension, diabetes, current smoker, hyperlipidemia, prior myocardial infarction [MI], prior percutaneous coronary intervention [PCI], prior coronary artery bypass graft surgery [CABG], prior congestive heart failure [CHF], prior stroke, renal insufficiency, CHF at presentation); body mass index (BMI) (categorized as underweight 18.5, normal 18.5 to 25, overweight 25 to 30, obese 30 to 40, or extremely obese 40 [calculated as weight in kilograms divided by height in meters squared]); heart rate and systolic blood pressure at presentation; electrocardiogram (ECG) findings (categorized as ST-segment depression, transient STsegment elevation, both, or neither); time of day and day of week at presentation (weekdays were defined as Monday to Friday and included daytime from 8 AM to 4 PM, evening from 4 PM to 12 AM, and night from 12 AM to 8 AM; weekends were defined as Saturday and Sunday and included daytime from 8 AM to 4 PM, evening from 4 PM to 12 AM, and night from 12 AM to 8 AM); year of presentation; attending physician (categorized as cardiologist or noncardiologist); hospital region (West, South, Midwest, Northeast); type of hospital (no catheterization laboratory; catheterization laboratory only, no PCI; PCI only, no onsite surgery; or PCI with on-site surgery); teaching hospital; and number of hospital beds. Holidays were categorized as weekdays if they fell on Monday to Friday and weekends if they fell on Saturday or Sunday. STATISTICAL ANALYSES We plotted the distribution of the delay from symptom onset to hospital presentation for the study population and performed tests of linear trend of the median delay times from calendar year 2001 through Continuous variables were presented as medians and 25th and 75th percentiles, while categorical variables were presented as frequencies. We used the Wilcoxon rank sum (2-sample) or Kruskal-Wallis (comparing more than 2-sample) test for continuous variables. To determine factors associated with longer delay from symptom onset to hospital presentation, continuous variables (such as age, BMI, and hospital beds) were investigated for nonlinear relationship with respect to delay time and indicated the use of categorical cut points. Because delay from symptom onset to hospital presentation is a skewed continuous variable, a logtransformation was applied to normalize the distribution. Plots of standardized residuals against predicted values of delay time demonstrated no evidence of heteroscedasticity. The estimated coefficients were transformed to their natural units to facilitate interpretation. 13 In determining the factors associated with delay from symptom onset to hospital presentation, linear generalized estimating equations with exchangeable working correlation matrix were used to account for within-hospital clustering because patients at the same hospital are more likely to have similar responses relative to patients at other hospitals (ie, withincenter correlation for responses). This method produces estimates similar to those from ordinary linear regression, but their variances are adjusted for the correlation of outcomes within a hospital. 14 The association between delay time and in-hospital mortality was explored using the logistic generalized estimating equations method with exchangeable working correlation matrix to account for within-hospital clustering. The mortality model adjusted for age, sex, race/ethnicity (white vs nonwhite), family history of coronary artery disease, hypertension, diabetes, current smoker, hyperlipidemia, prior MI, prior PCI, prior CABG, prior CHF, prior stroke, renal insufficiency, CHF at presentation, BMI, heart rate and systolic blood pressure at presentation, electrocardiogram findings (categorized as ST-segment depression, transient ST-segment elevation, both, or neither), and home medications (aspirin, angiotensin-converting enzyme inhibitor, statin, -blocker, and clopidogrel). The relationship between delay times and in-hospital mortality was not linear; therefore, we categorized delay time into 5 categories (0 to 1 hour, 1 to 2 hours, 2to3hours, 3 to 6 hours, and 6 hours) as clinically meaningful groupings. For modeling in-hospital mortality, patients who were transferred out were excluded since their survival status was not documented or available. The average percentage of missing data was less than 2% for the baseline covariates. For modeling, missing values for categorical variables were imputed to the lower-risk group (for instance, if diabetes status was missing, it was imputed as no diabetes), and missing values for continuous variables were replaced with sex-specific medians of nonmissing data. Patients with missing variables for age, sex, race, hospital region, and teaching hospital were excluded from the models because the clinicians did not believe that these covariates were appropriate for imputation. The impact of these imputations is an anticonservative es- 1835

3 timation of the standard errors of the covariates being estimated. With the size of this data set, we had adequate statistical power. We performed 2 sensitivity analyses. First, to minimize confounding from patients who are transferred-in from another hospital (n=23 788) as well as to determine the stability of our findings, we performed the analyses for the factors associated with delay time and the association of delay and outcomes by first excluding (main analysis) and then adding in patients who were transferred-in from another hospital. Second, we explored the impact of missing data imputation by carrying out a complete case analysis (n=91 316). Essentially, the results of these sensitivity analyses were similar (eg, direction and magnitude of the effects) to the main analyses, thus the results were not reported. P.05 was considered statistically significant for all tests, and all tests of statistical significance were 2-tailed. All analyses were performed using SAS software version 9.1 (SAS Institute Inc, Cary, North Carolina) by the Duke Clinical Research Institute. RESULTS STUDY POPULATION The overall study population included patients with non-stemi presenting at 568 hospitals who participated in CRUSADE between January 2001 and December Table 1 provides the baseline demographic, clinical, and hospital characteristics of the study population as well as the unadjusted presentation delay times observed with these subgroups. Time of symptom onset was not available for patients who were excluded from this analysis. The characteristics of the excluded patients compared with the study population are given in Table 2. Excluded patients had a slightly higher prevalence for patients with older age, female sex, and diabetes. Furthermore, those excluded patients had a lower prevalence of prior MI, PCI, or CABG, and a lower rate of hospital presentation during weekday or weekend nights ( 12 AM to 8 AM). The median delay time for the study population was 2.6 hours with an interquartile range of 1.3 to 6.0 hours during the study period (Figure 1). Approximately 59% of patients had delay times from symptom onset to hospital presentation greater than 2 hours, and 11% of patients presented more than 12 hours after onset of symptoms. Secular trend in delay from symptom onset to hospital presentation is shown Figure 2. There was no significant change in delay times from 2001 to 2006 (P=.16). MULTIVARIABLE ANALYSIS OF FACTORS ASSOCIATED WITH DELAY Multivariable analysis of factors associated with delay times from symptom onset to hospital presentation is given in Table 3. Compared with patients younger than 55 years, adjusted delay times were 3.9%, 8.1%, and 7.8% longer in age groups 65 to 74 years, 75 to 84 years, and 85 years or older, respectively (P). Men had 3.4% shorter delay times than women (P) and white patients had 2.2% shorter delay times than nonwhite patients (P=.03). Patients who have had prior MI or prior PCI had 3.6% and 3.9% shorter adjusted delay times compared with respective reference groups (P). Patients who presented during weekday daytime ( 8 AM to 4 PM) had the longest adjusted delay from symptom onset to hospital presentation. Compared with patients who presented during weekday daytime, those who presented during weekday evenings ( 4 PM to 12 AM), weekday nights ( 12 AM to 8 AM), weekend evenings ( 4 PM to 12 AM), and weekend nights ( 12 AM to 8 AM) had 10.9%, 24.7%, 15.8%, and 24.3% shorter delay times, respectively (P). MULTIVARIABLE ANALYSIS OF THE ASSOCIATION BETWEEN DELAY TIMES AND IN-HOSPITAL MORTALITY After adjusting for covariates and compared with the reference group of patients with delay times of more than 6 hours, the in-hospital mortality odds ratio (OR) was 1.19 (95% confidence interval [CI], ) for delay times of 0 to 1 hour or less, 0.91 (95% CI, ) for delay times of more than 1 to 2 hours, 0.77 (95% CI, ) for delay times more than 2 to 3 hours, and 0.90 (95% CI, ) for delay times more than 3 to 6 hours. The overall relationship between in-hospital mortality and delay time was not linear and generally not strong for patients with non-stemi. Patients who were taking the following home medications had lower adjusted in-hospital mortality rates: aspirin (OR, 0.91; 95% CI, ), angiotensinconverting enzyme inhibitor (OR, 0.87; 95% CI, ), and statin (OR, 0.88; 95% CI, ). However, home use of -blockers (OR, 0.95; 95% CI, ) or clopidogrel (OR, 1.01; 95% CI, ) was not associated with lower in-hospital mortality. COMMENT In our study of patients with non-stemi, we found that median delay time from symptom onset to hospital presentation was 2.6 hours, and 59% of patients had delay times greater than 2 hours. More importantly, delay time has not changed significantly from 2001 to 2006 among a contemporary, nationally representative cohort of patients with non- STEMI. Factors associated with longer delay from symptom onset to hospital presentation included patients with older age, female sex, nonwhite race, diabetes, and current smoking. Patients who presented during weekday or weekend nights (defined as 12 AM to 8 AM) had delay times 25% shorter than those who presented during weekday daytime (defined as 8 AM to 4 PM). Thus, identifying novel strategies for improving patient responsiveness to seek care is important in all patients who develop symptoms suggestive of myocardial ischemia. The factors associated with delay from symptom onset to hospital presentation have been well studied among patients with STEMI. Among a cohort of patients with STEMI enrolled in the National Registry of Myocardial Infarction from 1995 to 2004, geometric mean for delay time was 114 minutes. 2 Patient subgroups with a combination of risk factors (older age, women, Hispanic or black race, and/or diabetes) have particularly long delay times, which were 60 or more minutes longer than subgroups 1836

4 Table 1. Baseline Characteristics and Delay From Symptom Onset to Hospital Presentation Variable Patients, No. (%) Delay From Symptom Onset to Hospital Presentation, Median (IQR), h Age group (20.2) 2.6 ( ) (20.6) 2.5 ( ) (21.9) 2.6 ( ) (24.6) 2.7 ( ) (12.6) 2.7 ( ) BMI Underweight, (2.6) 2.8 ( ) Normal, 18.5 to (25.1) 2.7 ( ) Overweight, 25 to (33.4) 2.6 ( ) Obese, 30 to (27.1) 2.6 ( ) Extremely obese, (5.3) 2.6 ( ) Sex Male (59.9) 2.5 ( ) Female (39.9) 2.7 ( ) Race/ethnicity White (80.5) 2.6 ( ) Black (11.4) 2.9 ( ) Asian 1193 (1.1) 3.0 ( ) Hispanic 3687 (3.5) 2.8 ( ) Other/unknown 2185 (2.1) 2.9 ( ) Insurance status HMO/private (44.7) 2.5 ( ) Medicare (42.6) 2.7 ( ) Medicaid 5768 (5.5) 2.8 ( ) Self-pay/none 5991 (5.7) 2.7 ( ) Family history of CAD No (64.0) 2.6 ( ) Yes (34.0) 2.7 ( ) Hypertension No (28.5) 2.5 ( ) Yes (70.8) 2.7 ( ) Diabetes mellitus No (66.1) 2.6 ( ) Yes (33.3) 2.7 ( ) Current smoker No (72.9) 2.6 ( ) Yes (25.8) 2.7 ( ) Hyperlipidemia No (48.2) 2.6 ( ) Yes (50.7) 2.6 ( ) Prior MI No (67.7) 2.7 ( ) Yes (31.0) 2.5 ( ) Prior PCI No (76.5) 2.7 ( ) Yes (22.0) 2.5 ( ) Prior CABG No (78.5) 2.6 ( ) Yes (20.1) 2.6 ( ) Prior CHF No (79.7) 2.6 ( ) Yes (18.8) 2.7 ( ) Prior stroke No (87.4) 2.6 ( ) Yes (11.0) 2.6 ( ) Renal insufficiency No (83.9) 2.6 ( ) Yes (14.4) 2.7 ( ) CHF at presentation No (74.9) 2.6 ( ) Yes (24.1) 2.8 ( ) Heart rate, beats/min (23.8) 2.5 ( ) (75.8) 2.7 ( ) P Value, Global a (continued) 1837

5 Table 1. Baseline Characteristics and Delay From Symptom Onset to Hospital Presentation (continued) Variable Patients, No. (%) Delay From Symptom Onset to Hospital Presentation, Median (IQR), h Systolic blood pressure, mm Hg (96.3) 2.7 ( ) (2.9) 2.2 ( ) ECG findings Neither (63.0) 2.7 ( ) ST depression (30.3) 2.6 ( ) Transient ST elevation 5398 (5.2) 2.2 ( ) Both 1535 (1.5) 2.1 ( ) Time of presentation Weekday 8 AM to 4 PM (31.6) 3.1 ( ) 4 PM to 12 AM (24.0) 2.5 ( ) 12 AM to 8 AM (16.6) 2.2 ( ) Weekend 8 AM to 4 PM (10.9) 2.9 ( ) 4 PM to 12 AM 9980 (9.5) 2.3 ( ) 12 AM to 8 AM 7675 (7.3) 2.2 ( ) Year of presentation (21.9) 2.6 ( ) (23.9) 2.6 ( ) (21.6) 2.7 ( ) (17.9) 2.6 ( ) (14.8) 2.6 ( ) Primary attending Cardiologist (52.1) 2.7 ( ) Noncardiologist (46.9) 2.5 ( ) Hospital region West (11.8) 2.7 ( ) Northeast (23.5) 2.6 ( ) Midwest (33.8) 2.6 ( ) South (30.9) 2.7 ( ) Type of hospital No catheterization laboratory 6734 (6.4) 2.6 ( ) Catheterization laboratory only, no PCI 9956 (9.5) 2.4 ( ) PCI only, no on-site surgery 6826 (6.5) 2.5 ( ) PCI and on-site surgery (77.5) 2.7 ( ) Teaching hospital b No (73.0) 2.5 ( ) Yes (27.0) 2.9 ( ) Total hospital beds (14.4) 2.5 ( ) (21.6) 2.5 ( ) (21.1) 2.6 ( ) (17.0) 2.6 ( ) (25.9) 2.9 ( ) P Value, Global a Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CAD, coronary artery disease; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; ECG, electrocardiogram; HMO, health maintenance organization; IQR, interquartile range (25th and 75th percentile); MI, myocardial infarction; PCI, percutaneous coronary intervention. a P value calculated from Wilcoxon rank sum test (2-sample) and Kruskal-Wallis test (comparing more than 2-sample) for continuous variables. b Member of the Council of Teaching Hospitals. without those characteristics. Longer delay times were associated with a reduced likelihood of receiving any reperfusion therapy, and even among those treated, late presenters had significantly longer door-to-balloon and door-to-drug times. 3 However, secular trends in delay time and impact of longer delays on mortality are less understood in patients with non-stemi. Population-based studies that included all patients with acute MI (both STEMI and non- STEMI) found that longer delay from symptom onset to hospital presentation were more common among elderly patients, women, nonwhite patients, diabetic patients, and those with atypical symptoms. 7,9,15,16 Two prior studies have specifically evaluated delay time among patients with non- STEMI. Goldberg and colleagues 8 found that median delay time was 3.0 hours among 2935 patients with non- STEMI from the Global Registry of Acute Coronary Events (GRACE) registry. Factors associated with shorter delay time were male sex, presence of diaphoresis, ambulance transport, and symptom onset from 6 AM to before 12 AM (compared with 12 AM to 6 AM). In a study of 1219 patients with non ST-segment elevation acute coronary syndrome from the Canadian Acute Coronary Syndrome II registry, Elbarouni and colleagues 17 found that early presenters were more likely to be older, have prior angina or stroke, and have Killip class 1 compared with late pre- 1838

6 Table 2. Characteristics of Patients Excluded Owing to Lack of Documented Time of Symptom Onset Variable Study Population (N= ) Patients, No. (%) Excluded Cohort (n=26 604) P Value Age 55 y (79.7) (81.2) Female sex (39.8) (42.6) Nonwhite race (18.1) 5416 (20.4).11 Diabetes mellitus (33.3) 9505 (35.7) Prior MI (31.0) 7007 (26.3) Prior PCI (22.0) 4738 (17.8) Prior CABG (20.1) 4673 (17.6) Time of presentation Weekday 8 AM to 4 PM (31.6) 9665 (36.3) 4 PM to 12 AM (24.0) 6644 (25.0) 12 AM to 8 AM (16.6) 2989 (11.2) Weekend 8 AM to 4 PM (10.9) 2914 (11.0) 4 PM to 12 AM 9980 (9.5) 2401 (9.0) 12 AM to 8 AM 7675 (7.3) 1243 (4.7) Abbreviations: CABG, coronary artery bypass graft surgery; MI, myocardial infarction; PCI, percutaneous coronary intervention. Patients, % Delay From Symptom Onset to Hospital Presentation, h Figure 1. Distribution of delay from symptom onset to hospital presentation in the study population. Delay From Symptom Onset to Hospital Presentation, h (n = ) 2003 (n = ) (n = 22562) Calendar Year (n = ) (n = ) senters (defined as 6 hours from symptom onset). No differences were observed in use of medications, PCI, CABG, and in-hospital or 1-year mortality between early presenters (defined 6 hours from symptom onset) vs late presenters ( 6 hours from symptom onset). Our study is the largest, contemporary, nationally representative cohort of patients with non-stemi, and it advances the existing research in several respects. We found that delay time has not improved from 2001 to 2006 for patients with non-stemi. We also found that older patients, female patients, nonwhite patients, diabetic patients, and those with current smoking had longer delay times; however, the magnitude of effect ( 10%) on delay time from each factor was overshadowed by the overall duration of delay (median delay time, 2.6 hours). Therefore, interventions aimed at improving patient awareness of symptoms and responsiveness to seek care will likely need to target all patients at risk for MI, and not just those who have individual risk factors (age, sex, or diabetes) for longer delay time Our study also showed that patients with prior MI or PCI had modestly shorter delay times and those with prior CABG had similar delay times compared with respective reference groups. Efforts to improve patient responsiveness to seek care should target these subgroups with prior events or procedures. A potential educational intervention to improve delay time would be to routinely provide this during discharge planning or as a standard part of the office visit. The minimal reductions in delay times we observed suggest that current practice is failing to effectively educate and activate our patients. In addition, we found that delay times were 25% shorter during weekday or weekend nights from after 12 AM to 8 AM compared with weekday daytime from after 8 AM to 4 PM. This finding differs from previous studies that showed longer delays during the night. 8,15,21 While we cannot determine why patients decided to seek care more quickly Figure 2. Secular trends in delay (median value) from symptom onset to hospital. at night, potential hypotheses include heightened fear during the night when patients may be alone at home, higher tolerance of symptoms during the daytime when a patient is active or at work, or a perception of shorter waiting times and less crowding in emergency departments during the night. 22,23 We found that the relationship between delay time and in-hospital mortality for patients with non-stemi was not linear and generally not strong. First, patients with the shortest delay time (0-1 hour) had a higher risk of in-hospital mortality compared with the reference group (delay time 6 hours), whereas patients with delay times of more than 1 to 2 hours, more than 2 to 3 hours, and more than 3 to 6 hours had similar or slightly lower mortality compared with the reference group. Although we adjusted for many clinical variables, patients with the shortest delay time likely had greater disease severity at presentation that we did not measure and could not adequately adjust for. Patients with greater disease severity are likely to seek care early 24 and we have previously found that patients with STEMI with the shortest delay time also exhibited higher adjusted in-hospital mortality rate. 2,3 Second, the overall relationship between delay times and inhospital mortality was generally not strong for patients with non-stemi. Patient presentation can vary and evolve from unstable angina, to transient occlusion, and to complete occlusion of a coronary artery. Furthermore, in the absence of ST-segment elevation, there is no therapy that can provide a large benefit such as immediate reperfusion with primary PCI or fibrinolytics. Interestingly, home use of medications including aspirin, angiotensinconverting enzyme inhibitor, and statin were associated with lower adjusted in-hospital mortality. 1839

7 Table 3. Multivariable Model of Factors Associated With Delay From Symptom Onset to Hospital Presentation Variable Estimate (95% CI) a Global and Individual P Value, Age group, y (vs 55) 1.2 ( 3.2 to 0.9) (vs 55) 3.9 (1.4 to 6.5) (vs 55) 8.1 (5.4 to 10.9) 85 (vs 55) 7.8 (4.6 to 11.0) BMI group.80 Underweight (vs normal) 2.2 ( 2.1 to 6.7).32 Overweight (vs normal) 0.4 ( 2.1 to 1.3).61 Obese (vs normal) 0.2 ( 2.1 to 1.8).85 Extremely obese (vs normal) 0.1 ( 3.1 to 3.0).97 Male (vs female) 3.4 ( 4.7 to 2.1) White (vs nonwhite) 2.2 ( 4.2 to 0.3).03 Family history of CAD 2.4 (0.8 to 4.0).003 Hypertension 0.8 ( 0.7 to 2.3).29 Diabetes mellitus 4.2 (2.5 to 5.9) Current smoker 4.2 (2.4 to 6.0) Hyperlipidemia 0.2 ( 1.6 to 1.2).77 Prior MI 3.6 ( 5.0 to 2.2) Prior PCI 3.9 ( 5.4 to 2.3) Prior CABG 1.2 ( 0.3 to 2.8).12 Prior CHF 0.6 ( 1.2 to 2.5).50 Prior stroke 1.9 ( 4.0 to 0.3).09 Renal insufficiency 1.5 ( 0.6 to 3.6).17 Insurance status.16 Medicaid (vs HMO/private) 3.0 ( 0.2 to 6.3).07 Medicare (vs HMO/private) 1.0 ( 2.8 to 0.8).27 Self-pay/none (vs HMO/private) 0.4 ( 2.7 to 3.5).82 Time of presentation Weekday evening (vs weekday daytime) 10.9 ( 12.7 to 9.2) Weekday night (vs weekday daytime) 24.7 ( 26.2 to 23.0) Weekend daytime (vs weekday daytime) 5.6 ( 7.7 to 3.5) Weekend evening (vs weekday daytime) 15.8 ( 17.9 to 13.5) Weekend night (vs weekday daytime) 24.3 ( 26.4 to 22.2) Year of presentation (vs ) 0.2 ( 3.1 to 3.5) (vs ) 3.5 (0.3 to 6.8) (vs ) 1.1 ( 2.4 to 4.7) (vs ) 0.2 ( 3.2 to 3.7).92 No. of hospital beds (vs 200) 2.9 ( 8.9 to 3.6) (vs 200) 1.8 ( 4.8 to 8.8) (vs 200) 0.1 ( 7.1 to 7.9) (vs 200) 6.3 ( 0.9 to 14.0).09 Hospital region.21 Midwest (vs south) 1.9 ( 6.3 to 2.8).42 Northeast (vs south) 4.4 ( 9.3 to 0.7).09 West (vs south) 1.7 ( 4.1 to 7.9).57 Teaching (vs non-teaching) b 9.1 (3.8 to 14.7) Hospital facility type.46 Catheterization laboratory only, no PCI (vs PCI and on-site surgery) 6.1 ( 12.9 to 1.2).10 No catheterization laboratory (vs PCI and on-site surgery) 1.0 ( 7.8 to 6.3).78 PCI laboratory only, no on-site surgery (vs PCI and on-site surgery) 1.7 ( 9.4 to 6.6).68 Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CAD, coronary artery disease; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; CI, confidence interval; HMO, health maintenance organization; MI, myocardial infarction; PCI, percutaneous coronary intervention. a Calculation of estimate=100 (exp[ ] 1)%: the expected delay from symptom onset to hospital presentation changes by 100 (exp[ ] 1)% for each 1-unit change in the independent variable (eg, male vs female). b Member of the Council of Teaching Hospitals. This study calculated delay using the documented time fromsymptomonsettothetimeofhospitalarrival.thetime of symptom onset is subject to patient recall bias, language barriers, and socioeconomic status and relies on accurate documentation by each hospital participating in this registry. There is also the potential for survival bias because patients who died out-of-hospital and never presented are not included in this registry. Also, the type and nature of symptoms(continuous vs intermittent), socioeconomic status, marital status, and depression were not captured or included in the multivariable model. The mode of transport to the hospital (emergency medical services vs self-transport), number of hospitals per population density, distance to the nearest hospital, and traffic patterns were not included 1840

8 in the analysis because these variables were not collected in the CRUSADE registry. Patients who were transferred out were excluded from the in-hospital mortality model because their survival status was not available. In conclusion, the median delay time from symptom onset to hospital presentation among patients with non- STEMI was 2.6 hours and has not changed significantly from 2001 to Time of day had the largest impact on delay time; patients who presented to the hospital during weekday or weekend nights ( 12 AM to 8 AM) have 25% shorter delay times compared with those presenting during weekday daytime ( 8 AM to 4 PM). Novel strategies to improve patient responsiveness to seek care are critical and important for both patients with STEMI or non-stemi. Accepted for Publication: May 16, Author Affiliations: Division of Cardiovascular Diseases and Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota (Dr Ting); Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina (Ms Chen and Drs Roe, DeLong, and Peterson); Mid America Heart Institute of St Luke s Hospital and University of Missouri Kansas City, Kansas City (Drs Chan and Spertus); VA Health Services Research and Development Center for Excellence, Department of Medicine, University of Michigan Medical School, Ann Arbor (Dr Nallamothu); Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Dr Sullivan); Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine and Yale New Haven Hospital Center for Outcomes Research and Evaluation, New Haven, Connecticut (Drs Bradley and Krumholz). Correspondence: Henry H. Ting, MD, MBA, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN (ting.henry@mayo.edu). Author Contributions: Study concept and design: Ting, Roe, and Spertus. Acquisition of data: Ting, Chen, Roe, and Peterson. Analysis and interpretation of data: Ting, Chen, Roe, Chan, Spertus, Nallamothu, Sullivan, DeLong, Bradley, Krumholz, and Peterson. Drafting of the manuscript: Ting. Critical revision of the manuscript for important intellectual content: Ting, Chen, Roe, Chan, Spertus, Nallamothu, Sullivan, DeLong, Bradley, Krumholz, and Peterson. Statistical analysis: Ting, Chen, and DeLong. Obtained funding: Roe. Administrative, technical, and material support: Ting. Study supervision: Ting and Roe. Financial Disclosure: Dr Peterson has received research grants from Bristol-Myers Squibb/sanofi-aventis Pharmaceuticals Partnership, Merck/Schering, and Schering- Plough Corporation. Dr Roe was an investigator for BMS, Eli Lilly, Portola Pharmaceuticals, Schering-Plough, and sanofi-aventis and a consultant for Adolor, Astra Zeneca, BMS, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, sanofiaventis, and Schering-Plough. Funding/Support: CRUSADE is a national qualityimprovement initiative of the Duke Clinical Research Institute. CRUSADE is funded by the Schering-Plough Corporation. Bristol-Myers Squibb/sanofi-aventis Pharmaceutical Partnership provides additional funding support. Millennium Pharmaceuticals Inc also provided funding for this work. REFERENCES 1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation. 2007;116(7):e148-e Ting HH, Bradley EH, Wang Y, et al. Factors associated with longer time from symptom onset to hospital presentation for patients with ST-elevation myocardial infarction. Arch Intern Med. 2008;168(9): Ting HH, Bradley EH, Wang Y, et al. Delay in presentation and reperfusion therapy in ST-elevation myocardial infarction. Am J Med. 2008;121(4): Foraker RE, Rose KM, McGinn AP, et al. Neighborhood income, health insurance, and prehospital delay for myocardial infarction: the atherosclerosis risk in communities study. Arch Intern Med. 2008;168(17): Goff DC Jr, Feldman HA, McGovern PG, et al; Rapid Early Action for Coronary Treatment (REACT) Study Group. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Am Heart J. 1999; 138(6, pt 1): Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease. JAMA. 2000;284(1): Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Decade-long trends and factors associated with time to hospital presentation in patients with acute myocardial infarction. Arch Intern Med. 2000;160(21): Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol. 2002;89(7): McGinn AP, Rosamond WD, Goff DC Jr, Taylor HA, Miles JS, Chambless L. Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction. Am Heart J. 2005;150(3): Bhatt DL, Roe MT, Peterson ED, et al; CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-st-segment elevation acute coronary syndromes. JAMA. 2004;292(17): Mehta RH, Roe MT, Chen AY, et al. Recent trends in the care of patients with non- ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006;166(18): Dunlay SM, Alexander KP, Melloni C, et al. Medical records and quality of care in acute coronary syndromes: results from CRUSADE. Arch Intern Med. 2008;168 (15): Zhou XH, Stroupe KT, Tierney WM. Regression analysis of health care charges with heteroscedasticity. J R Stat Soc Ser C Appl Stat. 2001;50(3): Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1): Saczynski JS, Yarzebski J, Lessard D, et al. Trends in prehospital delay in patients with acute myocardial infarction (from the Worcester Heart Attack Study). Am J Cardiol. 2008;102(12): Goldberg RJ, Spencer FA, Fox KAA, et al. Prehospital delay in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009;103(5): Elbarouni B, Goodman SG, Yan RT, et al; Canadian ACS Registries Investigators. Impact of delayed presentation on management and outcome of non-stelevation acute coronary syndromes. Am Heart J. 2008;156(2): Dracup K, Alonzo AA, Atkins JM, et al; Working Group on Educational Strategies To Prevent Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction. The physician s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction. Ann Intern Med. 1997;126(8): Moser DK, Kimble LP, Alberts MJ, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke. Circulation. 2006;114(2): Dracup K, McKinley S, Doering LV, et al. Acute coronary syndrome: what do patients know? Arch Intern Med. 2008;168(10): Ottesen MM, Køber L, Jørgensen S, Torp-Pedersen C; TRACE Study Group: Trandolapril Cardiac Evaluation. Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction. Eur Heart J. 1996; 17(3): Bernstein SL, Aronsky D, Duseja R, et al; Society for Academic Emergency Medicine, Emergency Department Crowding Task Force. The effect of emergency department crowding on clinically oriented outcomes. Acad Emerg Med. 2009;16 (1): LaBounty T, Eagle KA, Manfredini R, et al. The impact of time and day on the presentation of acute coronary syndromes. Clin Cardiol. 2006;29(12): Dixon WC IV, Wang TY, Dai D, Shunk KA, Peterson ED, Roe MT; National Cardiovascular Data Registry. Anatomic distribution of the culprit lesion in patients with non-st-segment elevation myocardial infarction undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2008;52(16):

Utilization and Impact of Pre-Hospital Electrocardiograms for Patients With Acute ST-Segment Elevation Myocardial Infarction

Utilization and Impact of Pre-Hospital Electrocardiograms for Patients With Acute ST-Segment Elevation Myocardial Infarction Journal of the American College of Cardiology Vol. 53, No. 2, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.09.030

More information

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice 10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia

More information

Clinical Investigations

Clinical Investigations Clinical Investigations The Usage Patterns of Cardiac Bedside Markers Employing Point-of-Care Testing for Troponin in Non-ST-Segment Elevation Acute Coronary Syndrome: Results from CRUSADE Address for

More information

Older individuals are at greatest risk for developing and

Older individuals are at greatest risk for developing and Decade Long Trends (2001 2011) in Duration of Pre-Hospital Delay Among Elderly Patients Hospitalized for an Acute Myocardial Infarction Raghavendra P. Makam, MD, MPH; Nathaniel Erskine, BS; Jorge Yarzebski,

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital

More information

Mode of admission and its effect on quality indicators in Belgian STEMI patients

Mode of admission and its effect on quality indicators in Belgian STEMI patients 2015 Mode of admission and its effect on quality indicators in Belgian STEMI patients Prof dr M Claeys National Coordinator STEMI registry 29-6-2015 Background The current guidelines for the management

More information

Journal of the American College of Cardiology Vol. 45, No. 6, by the American College of Cardiology Foundation ISSN /05/$30.

Journal of the American College of Cardiology Vol. 45, No. 6, by the American College of Cardiology Foundation ISSN /05/$30. Journal of the American College of Cardiology Vol. 45, No. 6, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.11.055

More information

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients With Non ST-Segment Elevation Myocardial Infarction

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients With Non ST-Segment Elevation Myocardial Infarction Journal of the American College of Cardiology Vol. 50, No. 15, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.012

More information

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,

More information

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE

More information

The PAIN Pathway for the Management of Acute Coronary Syndrome

The PAIN Pathway for the Management of Acute Coronary Syndrome 2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina

More information

Awealth of research in acute coronary syndrome

Awealth of research in acute coronary syndrome CLINICAL TRIAL SUPPORT OF THE USE OF CRITICAL PATHWAYS IN IMPROVING PATIENT OUTCOMES Judy W. M. Cheng, PharmD, MPH, BCPS, FCCP * ABSTRACT Acute coronary syndrome (ACS) is a common condition encountered

More information

National Efforts to Improve Door-to-Balloon Time

National Efforts to Improve Door-to-Balloon Time Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.11.003

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Trends in Clinical, Demographic, and Biochemical Characteristics of Patients with Acute Myocardial Infarction from 2003 to 2008: A Report from the American Heart Association Get with the Guidelines Coronary

More information

Systems of Care to Improve Timeliness of Reperfusion Therapy for ST-Segment Elevation Myocardial Infarction During Off Hours

Systems of Care to Improve Timeliness of Reperfusion Therapy for ST-Segment Elevation Myocardial Infarction During Off Hours JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 1, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER DOI: 10.1016/j.jcin.2007.10.002 Systems of Care

More information

ORIGINAL INVESTIGATION. Clopidogrel to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge

ORIGINAL INVESTIGATION. Clopidogrel to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge ORIGINAL INVESTIGATION to Treat Patients With Non ST-Segment Elevation Acute Coronary Syndromes After Hospital Discharge Pierluigi Tricoci, MD; Matthew T. Roe, MD, MHS; Jyotsna Mulgund, MS; L. Kristin

More information

Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes JAMA. 2006;295:

Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes JAMA. 2006;295: ORIGINAL CONTRIBUTION Association Between Hospital Process Performance and Outcomes Among Patients With Acute Coronary Syndromes Eric D. Peterson, MD, MPH Matthew T. Roe, MD, MHS Jyotsna Mulgund, MS Elizabeth

More information

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD Disclosures Research contracts: AstraZeneca, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, The Medicines Company,

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Jean Skonhovd,RN,BSN,MSAS Emergency Department Director Avera Heart Hospital of South Dakota Time to Treatment is critical for STEMI patients

More information

National public health campaigns have attempted

National public health campaigns have attempted WINTER 2005 PREVENTIVE CARDIOLOGY 11 CLINICAL STUDY Knowledge of Cholesterol Levels and Targets in Patients With Coronary Artery Disease Susan Cheng, MD; 1,2 Judith H. Lichtman, MPH, PhD; 3 Joan M. Amatruda,

More information

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

The Strategic Reperfusion Early After STEMI study Implications for clinical practice The Strategic Reperfusion Early After STEMI study Implications for clinical practice Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization and Interventional

More information

Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction

Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 11, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.08.015 CLINICAL RESEARCH

More information

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research

More information

Antithrombotic Strategy in Non ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention

Antithrombotic Strategy in Non ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 6, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.03.015 Antithrombotic

More information

The Influence of Race on Health Status Outcomes One Year After an Acute Coronary Syndrome

The Influence of Race on Health Status Outcomes One Year After an Acute Coronary Syndrome Journal of the American College of Cardiology Vol. 46, No. 10, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.092

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of

More information

News the. Methods Data collection. The NCDR is a national registry of patients undergoing diagnostic cardiac catheterizations

News the. Methods Data collection. The NCDR is a national registry of patients undergoing diagnostic cardiac catheterizations Journal of the American College of Cardiology Vol. 52, No. 20, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.017

More information

Daily practice of ACS management in the Gulf: Data from Gulf COAST

Daily practice of ACS management in the Gulf: Data from Gulf COAST Daily practice of ACS management in the Gulf: Data from Gulf COAST Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Head, Division of Cardiology Mubarak Alkabeer Hospital

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total

More information

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute

More information

Continuing Medical Education Post-Test

Continuing Medical Education Post-Test Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on

More information

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group.

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR,

More information

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis

More information

From the a Duke Clinical Research Institute, Durham, NC, Singapore, Singapore,

From the a Duke Clinical Research Institute, Durham, NC, Singapore, Singapore, Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry Chee

More information

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Statin pretreatment and presentation patterns in patients with acute coronary syndromes Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos

More information

A Prior Myocardial Infarction: How Does it Affect Management and Outcomes in Recurrent Acute Coronary Syndromes?

A Prior Myocardial Infarction: How Does it Affect Management and Outcomes in Recurrent Acute Coronary Syndromes? A Prior Myocardial Infarction: How Does it Affect Management and Outcomes in Recurrent Acute Coronary Syndromes? Address for correspondence: Kim A. Eagle, MD University of Michigan Cardiovascular Center

More information

INTRODUCTION. Key Words:

INTRODUCTION. Key Words: Original Article Acta Cardiol Sin 2017;33:377 383 doi: 10.6515/ACS20170126A Percutaneous Coronary Intervention Predictors of Mortality in Elderly Patients with Non-ST Elevation Acute Coronary Syndrome

More information

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 10, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 10, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 10, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.07.008 Outcomes

More information

Life Science Journal 2016;13(5) Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study

Life Science Journal 2016;13(5)   Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study Samim Emet, MD 1, Fatih Akdogan 2, Yucel Arman 2, Murat Kose, MD 3, Basak Saracoglu, MD 4, Tufan Tukek, MD 3 1 Istanbul

More information

Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction

Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction Robert L. McNamara, MD, MHS a, Jeph Herrin, PhD a, Yongfei Wang, MS a, Jeptha P. Curtis,

More information

Clinical characteristics and treatment patterns of acute coronary syndrome in a predominantly African-descent population

Clinical characteristics and treatment patterns of acute coronary syndrome in a predominantly African-descent population RESEARCH ARTICLE Clinical characteristics and treatment patterns of acute coronary syndrome in a predominantly African-descent population Trecia McFarlane, Judith La Rosa, Luther Clark, Clinton Brown &

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative

More information

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,

More information

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN

DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and

More information

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36. Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005

More information

Myocardial infarction (MI) is the single largest killer of

Myocardial infarction (MI) is the single largest killer of Use of Emergency Medical Services in Acute Myocardial Infarction and Subsequent Quality of Care Observations From the National Registry of Myocardial Infarction 2 John G. Canto, MD, MSPH; Robert J. Zalenski,

More information

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants

More information

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group China PEACE risk estimation tool for inhospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic therapy Xi Li, Jing Li, Frederick A Masoudi, John

More information

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical

More information

Acute coronary syndromes (ACS), including unstable

Acute coronary syndromes (ACS), including unstable n report n Acute Coronary Syndromes: Morbidity, Mortality, and Pharmacoeconomic Burden Daniel M. Kolansky, MD Abstract Acute coronary syndromes (ACS), which include unstable angina and myocardial infarction

More information

Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes

Frequency and Clinical Implications of Discordant Creatine Kinase-MB and Troponin Measurements in Acute Coronary Syndromes Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.062

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Non#ST#Elevation Myocardial Infarction in the United States: Contemporary Trends in Incidence, Utilization of the Early Invasive Strategy, and In#Hospital Outcomes The Harvard community has made this article

More information

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early

More information

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Supplementary Online Content

Supplementary Online Content 1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing

More information

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative

Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative Trip J. Meine, MD, a Matthew T. Roe, MD, MHS, a Anita Y. Chen,

More information

Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA

Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after

More information

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the

More information

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from

More information

TAB 7: SUB TAB: AMI/CHEST PAIN Specifications & Paper Tools

TAB 7: SUB TAB: AMI/CHEST PAIN Specifications & Paper Tools TAB 7: SUB TAB: AMI/CHEST PAIN Specifications & Paper Tools Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Acute Myocardial Infarction

More information

DUKECATHR Dataset Dictionary

DUKECATHR Dataset Dictionary DUKECATHR Dataset Dictionary Version of DUKECATH dataset for educational use that has been modified to be unsuitable for clinical research or publication (Created Date and Time: 28OCT16 14:35) Table of

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Effect of Living Alone on Patient Outcomes After Hospitalization for Acute Myocardial Infarction

Effect of Living Alone on Patient Outcomes After Hospitalization for Acute Myocardial Infarction Effect of Living Alone on Patient Outcomes After Hospitalization for Acute Myocardial Infarction Emily M. Bucholz, MPH a, *, Saif S. Rathore, MPH a, Kensey Gosch, MS b, Amy Schoenfeld, BA a, Philip G.

More information

ORIGINAL INVESTIGATION. Do-Not-Resuscitate Orders in Patients Hospitalized With Acute Myocardial Infarction

ORIGINAL INVESTIGATION. Do-Not-Resuscitate Orders in Patients Hospitalized With Acute Myocardial Infarction Do-Not-Resuscitate Orders in Patients Hospitalized With Acute Myocardial Infarction The Worcester Heart Attack Study ORIGINAL INVESTIGATION Elizabeth A. Jackson, MD, MPH; Jorge L. Yarzebski, MD, MPH; Robert

More information

Original Research Factors Associated with Delay in Seeking Health Care for Hospitalized Patients with Acute Coronary Syndromes: The GREECS Study

Original Research Factors Associated with Delay in Seeking Health Care for Hospitalized Patients with Acute Coronary Syndromes: The GREECS Study Hellenic J Cardiol 47: 329-336, 2006 Original Research Factors Associated with Delay in Seeking Health Care for Hospitalized Patients with Acute Coronary Syndromes: The GREECS Study CHRISTOS PITSAVOS,

More information

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in

More information

Exercise treadmill testing is frequently used in clinical practice to

Exercise treadmill testing is frequently used in clinical practice to Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD

More information

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David

More information

Management of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police

Management of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police Management of STEMI in era of Reperfusion Eagles 2007 Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police STEMI in US ST Segment Elevation Myocardial Infarction (STEMI) ~500 K per year Thrombolysis

More information

OP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records.

OP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records. Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Chest Pain (CP) Set Measure ID # OP-4 * OP-5 * Measure Short Name Aspirin at Arrival

More information

Acute Coronary Syndromes: Different Continents, Different Guidelines?

Acute Coronary Syndromes: Different Continents, Different Guidelines? Acute Coronary Syndromes: Different Continents, Different Guidelines? Robert A. Harrington MD, MACC, FAHA, FESC Arthur L. Bloomfield Professor of Medicine Chair, Department of Medicine Stanford University

More information

In-hospital Mortality Characteristics of Women With Acute Myocardial Infarction

In-hospital Mortality Characteristics of Women With Acute Myocardial Infarction Elmer Press Original Article In-hospital Mortality Characteristics of Women With Acute Myocardial Infarction Lea Ann Matura Abstract Background: Cardiovascular disease continues to be the leading cause

More information

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index SUPPLEMENTAL MATERIAL Supplemental Methods Duke CAD Index The Duke CAD index, originally developed by David F. Kong, is an angiographic score that hierarchically assigns prognostic weights (0-100) based

More information

ST-elevation myocardial infarctions (STEMIs)

ST-elevation myocardial infarctions (STEMIs) Guidelines for Treating STEMI: Case-Based Questions As many as 25% of eligible patients presenting with STEMI do not receive any form of reperfusion therapy. The ACC/AHA guidelines highlight steps to improve

More information

Guide to GRACE manuscripts (1999 to 2006)

Guide to GRACE manuscripts (1999 to 2006) Guide to GRACE manuscripts (1999 to 2006) # Topic Year of publication (enrollment period) Patient group N Summary Reference 1. Overview: study design 2001 All ACS Aim: To explain the rationale behind GRACE

More information

Rural Minnesota STEMI Systems of Care

Rural Minnesota STEMI Systems of Care CARDIOVASCULAR HEALTH UNIT Rural Minnesota STEMI Systems of Care Almost 250,000 Americans experience ST-elevation Myocardial Infarction (STEMI), the deadliest form of heart attack, each year. Of approximately

More information

Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:

Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Results from the EXCEL Trial Suzanne J. Baron MD MSC on behalf of the EXCEL Investigators

More information

ORIGINAL INVESTIGATION. Twenty-Year Trends in the Incidence of Stroke Complicating Acute Myocardial Infarction

ORIGINAL INVESTIGATION. Twenty-Year Trends in the Incidence of Stroke Complicating Acute Myocardial Infarction ORIGINAL INVESTIGATION Twenty-Year Trends in the Incidence of Stroke Complicating Acute Myocardial Infarction Worcester Heart Attack Study Jane S. Saczynski, PhD; Frederick A. Spencer, MD; Joel M. Gore,

More information

CRUSADE - A Roadmap for Change:

CRUSADE - A Roadmap for Change: MARCH 2005 VOLUME 2 CRUSADE - A Roadmap for Change: 100,000 Patients Make a Difference Interim Analysis of the 100,000 Patients Enrollment Milestone March, 2005 Dear Colleagues: It is with great pleasure

More information

Keywords: Age, acute coronary syndrome, ST-elevation myocardial infarction, non-st-elevation myocardial infarction, unstable angina, death.

Keywords: Age, acute coronary syndrome, ST-elevation myocardial infarction, non-st-elevation myocardial infarction, unstable angina, death. 60 The Open Cardiovascular Medicine Journal, 2012, 6, 60-67 Open Access Effect of Age on Clinical Presentation and Outcome of Patients Hospitalized with Acute Coronary Syndrome: A 20-Year Registry in a

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes

Atrial Fibrillation and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes CLINICAL RESEARCH STUDY Atrial and Acute Myocardial Infarction: Antithrombotic Therapy and Outcomes Renato D. Lopes, MD, PhD, a Li Li, MS, a Christopher B. Granger, MD, a Tracy Y. Wang, MD, MHS, MSc, a

More information

Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice

Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela

More information

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences Dr. Henry H. Ting, Mayo Clinic College of Medicine Dr. James G. Jollis,, Duke University Medical Center Mayo Clinic STEMI System for Transferred

More information

Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative

Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Gregg C. Fonarow MD, Xin Zhao MS, Eric E. Smith MD, MPH, Jeffrey L. Saver MD, Mathew J. Reeves

More information

CURRENT QUALITY IMPROVEment

CURRENT QUALITY IMPROVEment ORIGINAL CONTRIBUTION Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non ST-Segment Elevation Acute Coronary Syndromes Karen P. Alexander, MD Anita Y. Chen, MS Matthew T. Roe,

More information

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.

Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:

More information

Regional Density Of Cardiologists And Mortality For Acute Myocardial Infarction And Heart Failure

Regional Density Of Cardiologists And Mortality For Acute Myocardial Infarction And Heart Failure Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2014 Regional Density Of Cardiologists And Mortality For Acute

More information

A Risk Score to Predict In-Hospital Mortality for Percutaneous Coronary Interventions

A Risk Score to Predict In-Hospital Mortality for Percutaneous Coronary Interventions Journal of the American College of Cardiology Vol. 47, No. 3, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.09.071

More information

Acute Reperfusion Therapy in STelevation Myocardial Infarction from

Acute Reperfusion Therapy in STelevation Myocardial Infarction from Dominican Scholar Collected Faculty and Staff Scholarship Faculty and Staff Scholarship 2007 Acute Reperfusion Therapy in STelevation Myocardial Infarction from 1994-2003 Brahmajee K. Nallamouthu Health

More information

Acute Coronary Syndrome. Sonny Achtchi, DO

Acute Coronary Syndrome. Sonny Achtchi, DO Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification

More information

A Report From the Second National Registry of Myocardial Infarction (NRMI-2)

A Report From the Second National Registry of Myocardial Infarction (NRMI-2) 1240 JACC Vol. 31, No. 6 Clinical Experience With Primary Percutaneous Transluminal Coronary Angioplasty Compared With Alteplase (Recombinant Tissue-Type Plasminogen Activator) in Patients With Acute Myocardial

More information